CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   995 Trials   3123 News 


«12...3637383940414243444546...5253»
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial (Channel 1) -  Feb 24, 2021 - Abstract #ELCC2021ELCC_47;    
    P3
    Consistently, confirmed ORR (64.8% [95% CI 57.6%–71.5%] vs 36.7% [95% CI 30.0%–43.9%], P < 0.0001) and DoR (median, 13.1 [95% CI 9.3–15.7] vs 4.4 [95% CI 4.2–4.9] months) per IRC favored the camrelizumab plus chemo group. Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.Conclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceConclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceptable safety profile, supporting this combination as an additional first-line treatment option for pts with advanced squamous NSCLC.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) (clinicaltrials.gov) -  Feb 23, 2021   
    P2,  N=190, Active, not recruiting, 
    Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.Conclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceConclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceptable safety profile, supporting this combination as an additional first-line treatment option for pts with advanced squamous NSCLC. Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Feb 2020
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial initiation date:  NEOPBOSCC: Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma (clinicaltrials.gov) -  Feb 10, 2021   
    P2,  N=108, Not yet recruiting, 
    Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Feb 2020 Initiation date: Dec 2020 --> Mar 2021
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Genomic profiling of advanced cervical cancer to predict response to PD-1 inhibitor combination therapy: A secondary analysis of the CLAP trial () -  Jan 29, 2021 - Abstract #SGO2021SGO_791;    
    P2
    Objectives: The CLAP trial (NCT03816553) is a multicenter, single-arm, phase II study in patients with metastatic, recurrent, or persistent cervical cancer who were treated with PD-1 inhibitor camrelizumab plus a VEGFR2 inhibitor apatinib. In this study, we uncovered PIK3CA, PTEN, ERBB3, PI3K pathway genes mutations and TMB as novel predictive biomarkers in cervical cancer patients treated with PD-1 inhibitor combination therapy, which might be of great clinical relevance in patient Stratification.
  • ||||||||||  Azopt (brinzolamide ophthalmic suspension 1%) / Novartis
    Journal:  An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. (Pubmed Central) -  Jan 23, 2021   
    Fewer interactions were reported for the anti-glaucoma agents, whereas synergistic combinations of celecoxib with antibiotics or SLC-0111 with various antitumor drugs were extensively investigated.Expert opinion. Drug interactions involving CAIs may be used both for monitoring the clinical efficacy of these agents when co-administered with other drugs but also for better controlling some diseases, such as hypoxic tumors, case for which the combination of CAIs with other anticancer agents (histone deacetylase inhibitors, alkylating agents, antimetabolite nucleosides, angiogenesis inhibitors and immune check point inhibitors) proved to be synergistic.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial initiation date:  NACI: Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) -  Jan 22, 2021   
    P2,  N=84, Recruiting, 
    Drug interactions involving CAIs may be used both for monitoring the clinical efficacy of these agents when co-administered with other drugs but also for better controlling some diseases, such as hypoxic tumors, case for which the combination of CAIs with other anticancer agents (histone deacetylase inhibitors, alkylating agents, antimetabolite nucleosides, angiogenesis inhibitors and immune check point inhibitors) proved to be synergistic. Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Dec 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  AMBITION: Neoadjuvant Therapy for Locally Advanced Colon Cancer (clinicaltrials.gov) -  Jan 19, 2021   
    P2,  N=64, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Dec 2020 Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date:  Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer (clinicaltrials.gov) -  Dec 28, 2020   
    P2,  N=100, Not yet recruiting, 
    Trial completion date: Jun 2022 --> Jun 2024 N=57 --> 100 | Trial completion date: May 2023 --> Aug 2024 | Initiation date: May 2020 --> Feb 2021 | Trial primary completion date: May 2021 --> Oct 2023
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    New P2 trial:  A Study of SHR-1210 (clinicaltrials.gov) -  Dec 22, 2020   
    P2,  N=250, Not yet recruiting, 
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal, Adverse events, Checkpoint inhibition:  Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. (Pubmed Central) -  Dec 20, 2020   
    ICI-related AEs were generally mild and tolerable for a predominantly Chinese cohort. However, we should pay attention to the combination of ICI with chemotherapy as it could increase grade 3-5 TRAEs and irAEs.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation (ePoster Hall) -  Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1534;    
    P2
    Table 1. Efficacy of camrelizumab and apatinib combination treatment in advanced NSCLC pts with EGFR mutation Conclusion Camrelizumab plus apatinib showed a moderate benefit in pts with EGFR mutated NSCLC and showed better efficacy in pts with EGFR 20ins or L858R mutation sub-types, warrant further investigation.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC (ePoster Hall) -  Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1530;    
    P2, P3
    The most common treatment-related adverse events of grade 3 or higher were hypertension (18 [17.1%]), palmar-plantar erythrodysesthesia syndrome (14 [13.3%]), and increased gamma-glutamyltransferase (10 [9.5%]). Conclusion Combined camrelizumab and apatinib had promising antitumor activity and acceptable safety in previously treated patients with advanced non-squamous NSCLC, especially in these with STK11 or KEAP1 mutation, phase III trial is ongoing for further validation (NCT04203485).